We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01269853
Recruitment Status : Recruiting
First Posted : January 4, 2011
Last Update Posted : December 2, 2017
Feinstein Institute for Medical Research
Information provided by (Responsible Party):
John A. Boockvar, Feinstein Institute for Medical Research

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 2018
  Estimated Study Completion Date : October 2018